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Abstract
Few data are available on treatment and outcome of methicillin-resistant (MR) staphylococcal prosthetic joint infections. Vancomycin
remains the treatment of choice for these infections, but its efﬁcacy and safety in bone-and-joint infections are insufﬁciently documented.
We conducted a prospective cohort study on 60 patients treated between November 2002 and December 2008 for chronic MR
staphylococcal (44 S. epidermidis, nine other coagulase-negative Staphylococcus and seven S. aureus) prosthetic hip infections (PHIs). Twenty-
two patients had previously undergone surgery for their PHI and 21 had previously received antibiotics. All patients had surgery (exchange
arthroplasty for 58 patients, resection arthroplasty for two) and received an antibiotic regimen combining high-dose continuous intravenous
vancomycin infusion (target serum concentration 30–40 mg/L) with another antibiotic for 6 weeks, followed by an additional 6 weeks of
oral intake. Two years after surgery, infection was considered cured in 41 (68%) patients and only two relapses occurred after one-stage
exchange arthroplasty. Nineteen (32%) patients experienced nephrotoxicity that was generally mild (RIFLE class R for 14 patients, class I for
four patients and class F for one patient) and most often reversible. Continuous high-dose intravenous vancomycin combination therapy is
an effective, feasible and reasonably safe treatment of chronic MR staphylococcal PHI.
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Introduction
Antibiotic treatment of prosthetic joint infections (PJIs) due to
Staphylococcus spp. is difﬁcult due to microbiological, pharma-
cokinetic and pharmacodynamic factors. First, the frequency of
antibiotic resistance is high among isolates responsible for PJI
[1], with 15–50% of isolates being methicillin-resistant (MR)
[2,3]. Second, phenotypic changes, such as bioﬁlm formation
and small-colony variants, further decrease antibiotic efﬁcacy
[4,5]. Finally, high antibiotic concentrations are difﬁcult to
achieve in bone [6], making cure of MR staphylococcal PJI
challenging. Data from randomized trials are lacking concern-
ing the duration, dose and choice of antibiotic(s) and
recommendations vary according to authors. To date, com-
bination therapy including vancomycin is still the treatment of
choice [7]. However, few studies have reported the use of
vancomycin for osteomyelitis or PJI [7–9].
Given vancomycin’s time-dependent antibacterial activity,
we have been administering it via continuous intravenous (IV)
infusion for many years [9]. Although its superiority over
intermittent administration has not been proven [10,11], this
mode of administration has several advantages. It simpliﬁes
nursing care, is very convenient for outpatient antibiotic
parenteral therapy (OPAT) and allows easy drug dose-
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monitoring and adaptation. Continuous IV vancomycin infusion
is therefore a coherent choice for the treatment of PJI due to
MR Staphylococcus spp.
Several factors encourage using high serum vancomycin
concentration for bone and joint infections. First, coagulase-
negative staphylococci isolated from orthopaedic-device-asso-
ciated infections often have decreased susceptibility to
teicoplanin and vancomycin, with MICs around 2–4 mg/L
[12]. Second, Norden reported an in vitro ten-fold vancomycin
MIC increase under anaerobic conditions analogous to those
of osteomyelitic bones in experimental rabbit osteomyelitis
[13]. Finally, the rate of penetration of vancomycin into
uninfected bone is 30–70% [14]. Based on these considerations
and despite limited clinical evidence, high-dose vancomycin has
been used to treat methicillin-resistant staphylococcal pros-
thetic joint infections [7].
The pharmacokinetic–pharmacodynamic parameter value
deﬁned as being predictive of vancomycin efﬁcacy is area under
the time–concentration curve (AUC)/MIC [13], and the
Infectious Diseases Society of America guidelines established
an AUC/MIC target value of 400 based on in vitro, animal and
limited human data. With a targeted serum vancomycin
concentration of 30–40 mg/L, our treatment modality
obtained AUC of 720–960 lg/mL/h and AUC/MIC  360–
480/h for MICs  2 lg/mL.
We conducted a prospective study to evaluate the safety,
efﬁcacy and feasibility of continuous IV high-dose vancomycin
infusion (CIVHD) combination therapy to treat prosthetic hip
infections (PHIs) due to MR Staphylococcus spp.
Materials and Methods
Study design and population
This prospective cohort study was carried out in a French
referral centre for bone-and-joint infections that manages
about 300 patients a year. All patients treated between
November 2002 and December 2008 for MR staphylococcal
PHI were eligible. Patients were included in the study if they
were  18 years old, underwent surgical treatment (exchange
or resection arthroplasty) and received combination antibiotic
therapy including CIVHD vancomycin infusion for at least
2 weeks. Patients with polymicrobial PHI including microor-
ganism(s) other than Staphylococcus and patients with positive
cultures of intra-operative specimens without clinical, biolog-
ical or radiological sign of infection, as deﬁned by Tsukayama
et al. [15], were excluded. Written informed consent was
obtained from all the patients and the study was approved by
the local ethics committee (CCP Ile-de-France VI).
Deﬁnition of cases and microbiology
Deﬁnitions of the terms used in this study are given in Table 1.
Preoperative joint aspirates and intra-operative samples were
handled as previously described [16]. Drug-resistance patterns
were determined with the disk diffusion method for all
specimens and for each colony with a different morphology
[4]. Vancomycin and teicoplanin minimum inhibitory concen-
trations (MICs) were determined by E-test (BioMerieux,
Marcy l’Etoile, France) for strains isolated from 47 patients.
Treatment modalities
All the patients underwent preoperative hip aspiration, as
described before [17], in order to conﬁrm and document PHI.
One-stage exchange arthroplasty was performed, provided
that no bone reconstruction was necessary and that the
microorganism had been isolated from preoperative joint
aspirates. The remaining patients underwent two-stage
exchange arthroplasty, except for two who underwent
resection arthroplasty.
Antibiotic therapy was begun during surgery, except for
patients with Staphylococcus aureus infection, for whom
treatment was started at least 2 days before surgery in
order to decrease the risk of postoperative systemic sepsis.
All the patients received combination therapy with  2
antibiotics. Vancomycin was administered IV through a
TABLE 1. Deﬁnitions of terms applied in this report
Term Deﬁnition
Staphylococcal
prosthetic hip
infection (PHI)
Isolation of Staphylococcus spp. from  2 cultures of
joint aspirate and/or intra-operative tissue
specimen associated with at least one of the
following criteria: a sinus tract communicating with
the prosthesis, purulence of the synovial ﬂuid at
the time of arthrocentesis or during surgery,
a synovial leukocyte count >1700/mL and
a differential of >65% neutrophils, or clinical
(local inﬂammatory signs including erythema,
swelling, warmth, pain), biological (elevated CRP)
and radiological signs (periosteal bone formation,
subchondral osteolysis) of PHI infection
MR Staphylococcus spp Staphylococcus spp. with oxacillin MIC >2 lg/mL
Multiresistance Resistance to  2 antibiotic families other than
b-lactams
Glycopeptides intermediate
susceptibility
MIC to vancomycin or teicoplanin >4 lg/mL
Resistance to glycopeptides MIC to vancomycin or teicoplanin >16 lg/mL
OPAT Outpatient parenteral antibiotic therapy
Cure Absence of clinical, biological and radiological
signs of PHI in a patient alive 2 years after
prosthesis removal
Relapse Signs of PHI and positive cultures of joint
aspirates or intra-operative specimens growing
the same bacterium within the 2 years following
prosthesis removal
Re-infection New PHI with another pathogen before 2 years
of follow-up
Infection-related death Death secondary to uncontrolled PHI-associated
sepsis before 2 years of follow-up
Treatment-related death Death associated with a complication arising during
or following surgery or while on antibiotic therapy
and in the absence of severe PHI-associated sepsis
MIC, minimum inhibitory concentration.
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central venous catheter with a loading dose (15 mg/kg)
infused over 60 min, followed immediately by continuous
infusion of 40–60 mg/kg/day, dissolved in 50 mL of 5%
dextrose and administered over a 12-h period twice daily
via an infusion pump. Combined antibiotics were prescribed
by the treating physician in accordance with antibiotic-
susceptibility testing results. Patients were discharged to
home with OPAT or transferred to a rehabilitation centre
until the end of parenteral therapy. At home, a visiting nurse
assured CIVHD administration once or twice a day through a
portable infusion device, either a constant infusion pump or
an elastomeric infusion system. Antibiotics were administered
IV for 6 weeks, followed by an oral regimen to complete
12 weeks whenever it was possible. No long-term oral
antimicrobial suppression was prescribed.
Treatment was monitored closely as described elsewhere
[18]. Serum vancomycin and serum creatinine concentrations
were determined twice a week. The target serum vancomycin
steady-state concentration was 30–40 mg/L, with lower and
higher values being considered to be under-dosed or over-
dosed, respectively; the daily vancomycin dose was then
increased or decreased (25% of the daily dose) accordingly. At
home, blood tests and vancomycin concentration determina-
tions were performed once a week.
All adverse events (AEs) considered by the treating
physician to be vancomycin related were reported, as were
reasons for discontinuation of other drugs. Nephrotoxicity
was deﬁned as a  50% increase of the serum creatinine level
from baseline, deﬁned as before starting this combined
regimen. Patients with acute renal failure were classiﬁed using
the RIFLE criteria (Risk of renal dysfunction, Injury to the
kidney, Failure of kidney function, Loss of kidney function and
End-stage kidney disease), which are highly sensitive for
diagnosis of vancomycin-associated acute renal failure [19],
and have a good prognostic value [20].
Outcomes
Patients were seen as outpatients at 6 weeks, 3, 6, 12 and
24 months and then once a year. Cure, relapse, re-infection
and infection-related or treatment-related death are deﬁned in
Table 1.
Statistical analyses
Fisher’s exact test and Wilcoxon’s rank-sum test were used to
identify characteristics associated with treatment insufﬁciency,
re-infection, or onset of renal insufﬁciency. Variables reaching
statistical signiﬁcance (p < 0.05) were subject to logistic
regression multivariate analysis. EPI info software version
3.5.1 was used for all analyses.
Results
Patients
During the study period, 265 PHIs were treated in our
department, among which 130 were staphylococcal PHI and 64
MR staphylococcal PHI (Fig. 1). Four of the latter patients, who
did not undergo surgery because of an advanced age
(>80 years) and numerous co-morbidities, received prolonged
antimicrobial therapy to limit symptoms of PHI without causing
excessive discomfort. They were excluded from this study.
Demographic and clinical characteristics of the remaining 60
PHIs included in this study are reported in Table 2.
Microbiology
Distribution and characteristics of the pathogens are given in
Table 3. Staphylococcus epidermidis was the most frequent
pathogen isolated in 44 PHIs, followed by other coagulase-
negative Staphylococcus in nine and S. aureus in only seven PHIs.
Treatment characteristics
Surgical treatment consisted of one-stage exchange arthro-
plasty for 32 patients, two-stage exchange arthroplasty for 26
and resection arthroplasty for two. Patients treated with
two-stage exchange arthroplasty had a longer past history of
PHI (median 747 days, range 55–3041 vs. 368 days, range
120–1681) and had been more frequently operated on
previously (14 out of 26 vs. 7 out of 32) than those treated
with one-stage exchange arthroplasty.
Vancomycin was administered for a median duration of 42
(range 14–70) days, and was initiated at a median daily dose of
40 (9–60) mg/kg. Doses were modiﬁed for 46 (77%) patients
during treatment, and median ([range) daily dose was 31
(5–58) mg/kg at the end of treatment. Gentamicin was
administered initially to 11 patients for a median duration of
10 (range 2–15) days, and was thereafter switched to another
antibiotic. Other combined antibiotics administered during the
ﬁrst 6 weeks of treatment were minocycline for 20 patients,
fusidic acid for 13, rifampin for 13, fosfomycin for seven,
clindamycin for two and linezolide and peﬂoxacin for one each.
Seven patients with S. aureus PHI received preoperative IV
antibiotic therapy including CIVHD vancomycin for a median
duration of 11 days (range 2–42).
During the second phase of treatment, 55 patients were
prescribed an oral regimen. Among the ﬁve other patients,
four had died (see outcome) and one patient developed a rash
5 days after taking minocyclin. This patient, infected with a
glycopeptide-intermediate multiresistant S. epidermidis (vanco-
mycin MIC 12, teicoplanin MIC 24 lg/mL and resistant to
ﬂuoroquinolones, rifampin, clindamycin, fucidic acid and
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cotrimoxazole), was treated with one-stage exchange arthro-
plasty and vancomycin combined with fosfomycin, for 30 days.
Fosfomycin was then stopped because of generalized edema,
and minocycline was started orally, but the patient developed a
cutaneous eruption 5 days later and minocyclin was
withdrawn. We therefore decided to stop deﬁnitively antibi-
otic therapy after 6 weeks. This patient was cured of his
infection.
TABLE 3. Distributions and characteristics of microorgan-
isms isolated from 60 prosthetic hip infections treated with
continuous IV high-dose vancomycin combination therapy
Variable Value
Strains
S. epidermidis (GIS) 44 (20)
S. aureus (GIS) 7 (1)
Other coagulase-negative staphylococci (GIS) 9 (2)
Resistance to other antibiotic classes
Fluoroquinolones 38
Fusidic acid 30
Clindamycin 39
Gentamicin 28
Rifampin 21
Fosfomycin 16
Cotrimoxazole 46
Tetracycline 12
Minocycline 0
Linezolida 1
Multiresistanceb 44
Glycopeptides MIC (lg/mL)c
Vancomycin, median [range] 3.5 [1.5–12]
Teicoplanin, median [range] 4 [1–96]
GIS, glycopeptide intermediate susceptibility.
Data are no. of episodes, unless otherwise indicated.
aSusceptibility to linezolid was determined for 11 patients.
bMultiresistance: resistance to  2 antibiotic families other than b-lactams.
cGlycopeptide E-test MICs were determined for 47 patients.
TABLE 2. Main demographic and clinical characteristics of
the 60 methicillin-resistant staphylococcal PHI episodes
treated with continuous IV high-dose vancomycin combina-
tion therapy
Variable Value
Demographic characteristics
Age–years, median [range] 70 [46–88]
Age >80 years 13 (22)
Males 29 (48)
Clinical characteristic
ASA scorea  3 8 (13)
BMI, median [range] 27 [17–46]
eGFR–mL/min, median [range] 90 [30–150]
Co-morbidity 13 (22)b
Cardiac insufﬁciency 2
Diabetes mellitus 10
Malignancy 5
BMI  30 23 (38)
Chronic viral hepatitis/cirrhosis 1/1
Alcoholism 2
HIV infection 1
PHI duration before surgery in our department,
days, median [range]
633 [55–3014]
PHI management before referral to us 22 (37)
Previous antibiotic therapy/including glycopeptides 22 (37)/8 (13)
Previous surgery for PHI 21 (35)
Data are no. (%) of all episodes, unless otherwise speciﬁed.
PHI, prosthetic hip infection; ASA, American Society of Anesthesiology; eGFR,
estimated glomerular ﬁltration rate, determined with the Cockcroft–Gault
formula; BMI, body mass index; HIV, human immunodeﬁciency virus.
aAccording to [21].
bTwo patients had two and one patient had three co-morbidities.
265 prosthetic hip 
infections (PHI)
135 non staphylococcal PHI
66 methicillin-susceptible 
staphylococcal PHI
60 pts included in this 
study
64 methicillin-
resistant 
staphylococcal PHI
Cure
41 pts
(68.3%)
4 patients (pts) had no 
surgical treatment
Unrelated death
3 pts
(5%)
Treatment failure15 pts  (25%)
Death related to the infection or its treatment: 4 pts (6.7%)
Relapse: 2 pts (3.3%)
Reinfection: 9 pts (15%)
1 pt lost to 
follow-up
(1.7%)
FIG. 1. Inclusion and outcome of patients.
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Twenty-seven patients received oral combination therapy,
including rifampin for 20, or minocycline or fusidic acid for nine
each. Five of them were treated with rifampin and ﬂuoroqu-
inolone, a combination that is associated with a better
outcome in patients with PJI due to S. aureus [22]. However,
one of the drugs was stopped in these ﬁve patients after
2–28 days because of adverse events (Achilles tendinitis in two
patients, vomiting or severe nausea in two patients, and
cutaneous eruption in one patient).
Twenty-eight patients received oral monotherapy, with
minocycline for 21, peﬂoxacin for ﬁve, fusidic acid for one and
linezolid for one. The outcome of patients treated with
monotherapy was not different from that of patients treated
with combination therapy (16% vs. 27% of treatment failure,
respectively; p = 0.27).
Adverse events
Nineteen patients developed renal insufﬁciency. Characteris-
tics of these patients and their risk factors for acute renal
insufﬁciency are shown in Table 4. Notably, among these 19
patients, ﬁve (26%) had received non-steroidal anti-inﬂamma-
tory drugs for 3–7 days to prevent postoperative heterotopic
ossiﬁcation [23], six (32%) had been treated with gentamicin
for 4–12 days, and ﬁve (26%) received diuretics or angioten-
sin-converting–enzyme inhibitors. Vancomycin was deﬁnitively
stopped for only one patient. According to the RIFLE criteria
[24], one patient was RIFLE class F, four patients class I, and 14
patients class R. Multivariate analysis did not retain any risk
factor associated with the occurrence of acute renal insufﬁ-
ciency (p > 0.05 for diabetes mellitus, baseline estimated
glomerular ﬁltration rate (eGFR) <90 or 45 mL/min, age
>70 years, or vancomycin overdose). While 16 patients’ serum
creatinine had returned to baseline values within 6 months
after surgery, it remained moderately elevated in three others.
Five patients experienced other vancomycin-related AEs:
leukopenia in four and fever in two (one associated with
leukopenia). Vancomycin was stopped for four of these
patients after a median duration of 25 (range 14–33) days.
Twelve patients suffered AEs related to other drugs, all of
which were withdrawn. Three patients experienced AEs
associated with their central venous catheter (infection,
thrombosis or pneumothorax).
Outcomes
After 2 years of follow-up, 41 (68%, 95% conﬁdence interval
(CI) 55.0–79.7) patients were considered cured (Fig. 1). None
of them relapsed thereafter, with a total median follow-up of
1377 (range 762–2279) days.
Two relapses occurred within 18 months after one-stage
exchange arthroplasty. The ﬁrst patient was infected with a
GIS S. epidermidis (vancomycin MIC 3 lg/mL, teicoplanin
12 lg/mL). He was treated intravenously for 6 weeks with
vancomycin combined with gentamicin for 6 days, relayed by
rifampin, then orally for 6 more weeks with minocycline and
rifampin. His infection relapsed 18 months later with an
S. epidermidis isolate that was rifampin resistant, but remained
minocycline susceptible, and glycopeptides MICs were not
increased. The second patient, also infected with S. epidermidis
(vancomycin MIC 2 lg/mL), received IV vancomycin and
rifampin for 6 weeks, followed by six additional weeks of oral
minocycline and rifampin. His infection relapsed 5 months
later with a GIS isolate (vancomycin MIC 3 lg/mL, teicopl-
anin 24 lg/mL), but was still susceptible to rifampin and
minocycline. Because of the low number of patients, univariate
analysis was unable to identify any risk factor for relapse.
Nine patients developed prosthetic hip re-infection (15.0%,
95% CI 7.1–26.6). Seven and one of them had undergone
two-stage and one-stage exchange arthroplasty, respectively,
TABLE 4. Incidence, characteristics and risk factors for acute renal insufﬁciency episodes
Variable
No RI during treatment RI during treatment
p value RR (95% CI)n = 41 n = 19 (32%)a
eGFR–mL/min, mean  SD
At the start of treatment 87  37 107  34 0.056b
At the end of treatment 87  39c 61  20d 0.02b
Age, years, mean  SD 68  11 70  11 0.0726b
Van discontinuation before day 40 (no.) 8 2d 0.35 1.7 (0.41–7.46)
Associated conditions (no.)
Van overdose 24 17 0.015 1.53 (1.13–2.06)
Age >80 years 8 5 0.39 1.14 (0.71–1.82)
Gentamicin treatment 5 6 0.077 1.62 (0.83–3.16)
Diabetes mellitus 8 2 0.32 0.83 (0.57–1.19)
Baseline eGFR <60 mL/min 11 1 0.021 0.66 (0.50–0.86)
RI, renal insufﬁciency; eGFR, estimated glomerular ﬁltration rate, determined by Cockcroft–Gault formula; Van, vancomycin.
p values were determined using Fisher’s exact test, unless otherwise indicated.
aAmong the 19 episodes of renal insufﬁciency, four were considered unrelated to vancomycin (three patients had acute urinary tract obstruction, one patient had minocycline-
induced drug reaction with eosinophilia and systemic symptom (DRESS)).
bDetermined using Wilcoxon’s rank-sum test.
cp = 0.71 vs. start of treatment (Wilcoxon’s rank-sum test).
dp = 0.0001 vs. start of treatment (Wilcoxon’s rank-sum test).
eVancomycin was stopped because of the treatment-unrelated death of one patient and minocycline-induced DRESS syndrome with renal insufﬁciency in another.
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and one had undergone resection arthroplasty. Univariate
analysis identiﬁed type of surgery as the only factor signiﬁcantly
associated with re-infection (p = 0.026 for two-stage
exchange arthroplasty, with a relative risk (RR) of 1.29 (95%
CI 1.0 1–1.65), and p = 0.008 for one-stage exchange arthro-
plasty, with a RR of 0.74 (95% CI 0.59–0.94)).
Four treatment-related deaths occurred (6.7%, 95% CI 1.8–
16.2): one postoperative cardiogenic shock, two postoperative
septic shocks due to Gram-negative bacteria and one infection-
related septic shock due to a toxic shock syndrome toxin-
secreting S. aureus following one-stage exchange arthroplasty.
Three patients died of unrelated causes before completing
2 years of follow-up (5%, 95% CI 1.0–13.9); one patient was
lost to follow-up. Deaths related to the infection or its
treatment were signiﬁcantly more frequent in patients with
S. aureus infections (43% of patients with an S. aureus infection,
vs. 2% of patients with a coagulase-negative Staphylococcus
infection, p = 0.004), with a relative risk of 1.72. The rate of
treatment failure was superior in patients with S. aureus
infection (57% vs. 21% in patients with infection due to a
coagulase-negative Staphylococcus sp.), but it includes very
different events (one re-infection, one postoperative septic
shock due to a TSST-secreting S. aureus and two postoperative
deaths unrelated to the infection) and the difference did not
reach statistical signiﬁcance (p = 0.06).
Overall, 15 patients experienced treatment failure (25.0%,
95% CI 14.7–37.9). Eight, ﬁve and two of these patients had been
treated with two-stage, one-stage exchange arthroplasty and
resection arthroplasty, respectively (p = 0.25, 0.08 and 0.06).
Discussion
The species most commonly responsible for PJI belong to the
Staphylococcus genus, with coagulase-negative staphylococci
accounting for almost half of all infections [25]. Choosing
optimal antibiotic therapy for MR staphylococcal PJI is an
important issue, as multiresistance is often encountered
among S. epidermidis isolates [26, 27]. Although new anti-
Staphylococcus antibiotics have recently been developed,
vancomycin remains the treatment of choice [10,25].
Herein we described a prospective cohort of 60 patients
with MR staphylococcal PHI treated with CIVHD vancomycin
combination therapy. To our knowledge, this is the largest
cohort of MR staphylococcal prosthetic joint infection. Two
main conclusions can be drawn from this study. First, despite
the high percentage of previously unsuccessfully treated
patients and multiresistant or GIS strains, the outcomes were
satisfactory, showing that the treatment protocol presented
here was effective. The overall 2-year survival rate without
treatment failure was 68%, and only two relapses (3.3%) had
been identiﬁed. Treatment failure, including very different
events as relapse, re-infection and infection- or treatment-
related death, was observed in 25% of patients (95% CI 14.7–
37.9). These results are close to those reported previously for
staphylococcal PJI [8,22,28]. The precise role of vancomycin is
difﬁcult to analyse, because all patients were treated with
combination antibiotic therapy. Likewise, it is impossible to
determine whether the high-dose vancomycin regimen used
here, based on pharmacokinetic/pharmacodynamic consider-
ations, is more effective than the conventional-dose treatment.
Available data are insufﬁcient to answer these questions,
because only three studies on vancomycin treatment for bone-
and-joint infections due to various Gram-positive bacteria [7–
9] have been published. In these studies, vancomycin was
administered for 3–6 months. Targeted steady-state or trough
concentrations ranged from 20 to 40 mg/L. In all these studies,
vancomycin was used in combination with various antibiotics
(rifampin, ciproﬂoxacin, fusidic acid or fosfomycin). Cures
were obtained for 67–97% of the patients after 6–24 months
of follow-up.
The second conclusion of this study is that CIVHD
vancomycin infusion was associated with frequent but mild
nephrotoxicity. Serum creatinine rose  50% in 32% of the
patients during treatment (Table 4). Vancomycin overdose
(serum level >40 mg/L) was the only risk factor for occurrence
of renal insufﬁciency identiﬁed in univariate analysis. This
ﬁnding agrees with several studies showing that high vanco-
mycin doses increased the risk of nephrotoxicity [29–31]. In
our cohort, vancomycin-attributed nephrotoxicity was mod-
est, being most often classiﬁed ‘risk’ according to the RIFLE
criteria, usually associated with another favouring condition,
and in most cases was reversible upon drug withdrawal. The
role of the vancomycin administration mode in the onset of
renal insufﬁciency remains controversial. Ingram et al. [32]
compared the nephrotoxicity rates of patients receiving
intermittent or continuous vancomycin infusion(s) and showed
that they were similar but occurred later in the continuous-
infusion group. In a prospective study [7], fewer AEs neces-
sitating vancomycin discontinuation occurred in patients
treated with continuous IV vancomycin administration (8.7%)
than in those receiving intermittent infusions (42.9%). Due to
its design, our study does not provide further evidence for the
protective effect of continuous vancomycin infusion against
renal insufﬁciency. Surprisingly, we observed signiﬁcantly less
acute renal insufﬁciency in patients with impaired baseline
renal function (Table 4). This paradoxical relationship might be
explained by more aggressive hyperhydratation, or closer
monitoring of serum vancomycin levels in this subset of
patients, but no signiﬁcant association could be identiﬁed
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between impaired basal eGFR and vancomycin overdose
(p = 0.47 with Fisher’s exact test).
In our study, patients who underwent a two-stage exchange
arthroplasty had a higher risk of re-infection than patients who
underwent a one-stage exchange arthroplasty (26.9% vs. 3.1%,
respectively). There may be several explanations for this
difference. First, two-stage exchange arthroplasty implies two
operations, which obviously increases the risk of surgical site
infection. Second, two-stage exchange arthroplasty was per-
formed in more severe patients who had important bone
defects and needed large bone reconstruction. These patients
had a longer past history of PHI and they had been more
frequently operated on previously than patients with one-stage
exchange. Therefore, these patients with poorer tissue quality
surrounding the prosthesis are probably at higher risk of
surgical site infection.
The main limitation of this study is its non-comparative
design, which did not enable us to draw precise conclusions
about impact of CIVHD vancomycin infusion on cure and
treatment-related AE rates. Another limitation is its mono-
centric design. In our centre, CIVHD is frequently used to
treat bone-and-joint infections. Medical and nursing staffs are
used to management of this therapy, which is crucial for
patient safety. Notably, 42% of patients received CIVHD
vancomycin infusion at home, which shows that this approach
is feasible and easy to set up.
In conclusion, we report here our experience treating MR
staphycoloccal PHI with combination therapy including CHDIV
vancomycin infusionwith a satisfactory success rate, despite a high
prevalence of multiresistant and GIS strains. Thirty-two per cent
of the patients suffered nephrotoxicity, whichwas usually mild and
reversible. The use of adjunctive antibiotic(s) with excellent bone
diffusion and activity against all the isolated strains, thorough
excision and complete removal of the infected material are other
major considerations in achieving maximal efﬁcacy. Management
of these severe and difﬁcult-to-treat infections requires a
specialized and experienced multidisciplinary approach.
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